Study Details

Back to Search Results

A study of ASP3082 in adults with previously treated solid tumors

This trial is recruiting
The study is currently recruiting participants.

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT05382559

Astellas Study ID

The unique identification code given by the study sponsor.

3082-CL-0101

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Advanced/Metastatic Cancer

Phase

These clinical trials are usually the first time an experimental treatment is studied in a small group of people.

Phase 1

Age

18 Years - N/A

Sex

Female & Male

Product

ASP3082

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jun 2022 - Oct 2026

Masking

None (Open Label)

Enrollment number

356

A Phase 1 Study of ASP3082 in Participants with Previously Treated Locally Advanced or Metastatic Solid Tumor Malignancies with KRAS G12D Mutation

Study summary

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of ASP3082 in adults with previously treated solid tumors? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

NEXT Oncology

San Antonio, United States, 78229

Recruiting
Contact Us

Sarah Cannon Research Institute

Nashville, United States, 37203

Recruiting
Contact Us

Columbia University - Herbert Irving Comprehensive Cancer Center

New York, United States, 10032

Recruiting
Contact Us

Florida Cancer Specialists & Research Institute Sarasota

Sarasota, United States, 34232-6422

Recruiting
Contact Us

NEXT Oncology - Virginia Cancer Specialists

Fairfax, United States, 22031

Recruiting
Contact Us

Memorial Sloan Kettering Cancer Center

New York, United States, 10065

Recruiting
Contact Us

UCLA Santa Monica Hematology Oncology

Santa Monica, United States, 90404

Recruiting
Contact Us

University of Kansas Medical Center

Westwood, United States, 66205

Recruiting
Contact Us

Vanderbilt University Medical Center

Nashville, United States, 37232

Recruiting
Contact Us

Smilow Cancer Center at Yale New Haven Hospital

New Haven, United States, 06520-8028

Recruiting
Contact Us

Washington University School of Medicine

St. Louis, United States, 63110

Recruiting
Contact Us

Dana Farber Cancer Institute

Boston, United States, 02215

Recruiting
Contact Us

Cancer Institute Hospital of JFCR

Koto-ku, Japan

Recruiting
Contact Us

National Cancer Center Hospital

Chuo-ku, Japan

Recruiting
Contact Us

National Cancer Center Hospital East

Kashiwa, Japan

Recruiting
Contact Us

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo